Document is current
Any future updates will be listed below
-
Authors
Hohmann, Lennart
Nacer, Deborah F.
Aine, Mattias
Memari, Yasin
Black, Daniella
Bowden, Ramsay
Davies, Helen R.
Borg, Åke
Vallon-Christersson, Johan
Nik-Zainal, Serena
Staaf, Johan
-
Funding
Funding for this research was provided by:
Lund University
- License Information
-
More Information
Article History
Received: 13 May 2025
Accepted: 6 November 2025
First Online: 1 December 2025
Declarations
:
: The SCAN-B study (ClinicalTrials.gov ID NCT02306096) [ , ] is approved by the Regional Ethical Review Board in Lund, Sweden (registration numbers 2009/658, 2010/383, 2012/58, 2013/459, 2014/521, 2015/277, 2016/541, 2016/742, 2016/944, 2018/267) and the Swedish Ethical Review Authority (registration numbers 2019–01252, 2024–02040-02). All patients provided written informed consent prior to enrolment, and all analyses were performed in accordance with patient consent and ethical regulations and decisions. Ethical approvals and patient consent procedures for the METABRIC [ ], BASIS [ ], and TCGA [ ] cohorts are reported in the respective original publications, and all analyses in the present study were conducted in accordance with these approvals and the associated ethical regulations. This study conformed to the principles of the Helsinki Declaration.
: Not applicable.
: S.N.-Z. and H.R.D. hold patents or have submitted applications on clinical algorithms of mutational signatures: HRDetect (PCT/EP2017/060294), clinical use of signatures (PCT/EP2017/060289) and clinical predictor (PCT/EP2017/060298. S.N.Z. also holds the following patents: MMRDetect (PCT/EP2022/057387), rearrangement signature methods (PCT/EP2017/060279) and hotspots for chromosomal rearrangements (PCT/EP2017/060298). Two further patent filings have been made recently (numbers are pending). All other authors declare that they have no competing interests.
